Design Therapeutics, Inc.

DT-216P2 Anticipated Milestones: Registrational Plan Update in Q4 2026 and 12-Week RESTORE-FA Data in Q1 2027 Cash and securities of $208.6 million at quarter-end provide strong financial runway CARLSBAD, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today reported third quarter 2026 financial results and highlighted business updates and upcoming milestones across its GeneTAC® portfolio.

Design Therapeutics is initiated with a "Hold" rating as its lead candidate, DT-216P2 targets the root cause of Friedreich Ataxia [FA]. The company's 4-week phase 1/2 RESTORE-FA data showed strong biomarker and clinical improvements, but confirmation awaits 12-week results in Q1 2027. Upcoming catalysts include a registrational update in Q4 2026 for DT-216P2 FA and early-stage readouts for DM1 and FECD programs in 2027.

Design Therapeutics, Inc. (NASDAQ: DSGN - Get Free Report) has received an average recommendation of "Moderate Buy" from the eight research firms that are presently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, six have assigned a buy recommendation and one has assigned a strong buy recommendation

Bank of New York Mellon Corp acquired a new position in shares of Design Therapeutics, Inc. (NASDAQ: DSGN) in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 92,069 shares of the company's stock, valued at approximately $1,332,000. Bank of New York